Loading...
Nonadherence to evidence-based therapies remains an important barrier to good clinical outcomes in our patients at risk for cardiovascular disease (CVD). To test the hypothesis that medication costs contribute to the problem of nonadherence, researchers evaluated 2013–2017 data from the cross-sectional annual National Health Interview Survey.
Of the 14,279 respondents over age 18 with self-reported atherosclerotic CVD (ASCVD), 12.6% (equivalent to an estimated 2.2 million U.S. adults) reported skipping medications in the previous year because of financial concerns (skipping doses, taking less medication, or postponing filling a prescription). Patients under age 65, women, and people with low income, lack of health insurance, or multiple como…